Fortress Biotech Q4 Earnings Report: Analysts Predicted Loss

Fortress Biotech Inc Surpasses Expectations with Reduced Quarterly Loss

In a noteworthy financial update, Fortress Biotech Inc has unveiled its quarterly results for the period concluded in December, presenting a loss per share markedly lower than anticipated. Contrary to the consensus compiled from five analysts, who forecasted a per-share loss of $1.97, the biopharmaceutical company reported a substantially better outcome, with an adjusted quarterly loss of merely 53 cents per share.